Aslam M Imran, Cardile Anthony P, Crawford George E
Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
J Int Assoc Provid AIDS Care. 2014 Jan-Feb;13(1):22-3. doi: 10.1177/2325957413502539. Epub 2013 Sep 13.
Thrombocytopenia is frequently encountered in HIV-infected patients, and the predominant cause is primary HIV-associated thrombocytopenia (PHAT). Standard treatment regimens include optimization of antiretroviral therapy, intravenous immunoglobulin, anti-D, and corticosteroids. Retreatment due to the inability to sustain remission or inferior responses is common, and investigation into the safety and efficacy of alternative therapies is warranted. We describe novel and effective treatment of PHAT with the peptide thrombopoietin receptor agonist romiplostim in a patient with a minimal response to conventional therapy.
血小板减少症在HIV感染患者中经常出现，主要原因是原发性HIV相关血小板减少症（PHAT）。标准治疗方案包括优化抗逆转录病毒疗法、静脉注射免疫球蛋白、抗-D和皮质类固醇。由于无法维持缓解或反应不佳而进行再次治疗很常见，因此有必要研究替代疗法的安全性和有效性。我们描述了在一名对传统疗法反应极小的患者中，使用肽促血小板生成素受体激动剂罗米司亭对PHAT进行的新颖且有效的治疗。
